Date: 2012-04-17
Type of information: Fundraising
Company: Imaxio (France)
Investors: Pradeyrol Développement (France)
Amount: €2.9 million
Funding type: financing round
Planned used: This latest injection of funds will enable Imaxio to speed up its organic growth through two major R&D projects (clinical development of IMX313 vaccine-carrying protein platform, which is designed to improve the efficacy of vaccinations against various diseases in humans (such as tuberculosis, malaria and cancers) as well as in animals and international commercialization of its vaccine against human leptospirosis, Spirolept, which is already marketed in France).
Others: Imaxio has recently finalized a funding round in which it raised €2.9 million from its principal shareholder, Pradeyrol Développement. This latest injection of funds will enable Imaxio to speed up its organic growth through two major R&D projects.
The first is the clinical development of its IMX313 vaccine-carrying protein platform, which is designed to improve the efficacy of vaccinations against various diseases in humans (such as tuberculosis, malaria and cancers) as well as in animals. IMX313 is scheduled to enter clinical development in 2013, and by the end of next year preclinical proof of principle is expected to be established in new indications. Imaxio is thus seeking to conclude co-development and industrial partnership agreements for IMX313 for the purpose of having its carrier protein technology incorporated in new vaccines.
The second project is the international commercialization of its vaccine against human leptospirosis, Spirolept, which is already marketed in France. The company wants to complete the update of its marketing authorization application so as to be able to submit additional applications in other European countries starting in 2015.
Therapeutic area: Cancer - Oncology - Infectious diseases
